Literature DB >> 2509217

A-69024: a non-benzazepine antagonist with selectivity for the dopamine D-1 receptor.

D J Kerkman1, M Ackerman, L D Artman, R G MacKenzie, M C Johnson, L Bednarz, W Montana, K E Asin, H Stampfli, J W Kebabian.   

Abstract

A-69024 HBr, 1-(2-bromo-4,5-dimethoxybenzyl)-7-hydroxy-6-methoxy-2-methyl-1,2,3,4- tetrahydroisoquinoline hydrobromide, is a selective antagonist of the dopamine D-1 receptor. A-69024 HBr shows an apparent affinity toward the D-1 receptor (identified using [125I]SCH 23390) of 12.6 (4.15-38.3) nM (mean (90% CL), n = 3); the apparent affinity toward the D-2 receptor (identified using [3H]spiroperidol is 1 290 (1,200-1,380) nM (n = 3); using [125I]lysergic acid diethylamine to identify the 5-HT1C receptor gives apparent affinity of 17,800 (9,700-32,600) nM (n = 3). In assays of adenylate cyclase activity, A-69024 HBr antagonizes the D-1 receptor with a calculated affinity of 43.9 (17.5-110) nM (n = 5), while the molecule antagonizes the D-2 receptor with a calculated affinity greater than 400 nM. Behavioral studies demonstrate that A-69024 HBr (5 mg/kg s.c.) is able to block both amphetamine-induced locomotor activity and apomorphine-induced stereotypy. Furthermore, A-69024 HBr blocks SF&F 38393-, but not quinpirole-, induced rotation in rats having unilateral 6-hydroxydopamine lesions of the substantia nigra. When administered at behaviorally effective doses. A-69024 HBr neither increases the concentration of serum prolactin nor potentiates dihydroxyphenylalanine (DOPA) accumulation in the caudate-putamen of rats pretreated with the DOPA decarboxylase inhibitor NSD 1015. Because A-69024 is a dopamine receptor antagonist discriminating between the D-1 and D-2 receptors, it may be a useful research tool.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2509217     DOI: 10.1016/0014-2999(89)90362-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Neuroanatomical substrates mediating the aversive effects of D-1 dopamine receptor antagonists.

Authors:  T S Shippenberg; R Bals-Kubik; A Huber; A Herz
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity.

Authors:  R Markstein; P Gull; C Rüdeberg; S Urwyler; A L Jaton; K McAllister; A K Dixon; D Hoyer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  D1 receptor binding in rat striatum: modification by various D1 and D2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function.

Authors:  S C Cheetham; C J Kettle; K F Martin; D J Heal
Journal:  J Neural Transm Gen Sect       Date:  1995

4.  Quantification of SCH 39166, a novel selective D1 dopamine receptor antagonist, in rat brain and blood.

Authors:  J Hietala; T Seppäla; J Lappalainen; E Syvälahti
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.

Authors:  K K Gnanalingham; A J Hunter; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.